517 related articles for article (PubMed ID: 31427295)
1.
Flamm RK; Shortridge D; Castanheira M; Sader HS; Pfaller MA
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427295
[TBL] [Abstract][Full Text] [Related]
2. Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013).
Flamm RK; Castanheira M; Streit JM; Jones RN
Diagn Microbiol Infect Dis; 2016 Jul; 85(3):352-355. PubMed ID: 27112832
[TBL] [Abstract][Full Text] [Related]
3. Trends in the susceptibility of U.S.
Pfaller MA; Shortridge D; Carvalhaes CG; Castanheira M
Microbiol Spectr; 2023 Dec; 11(6):e0198123. PubMed ID: 37921464
[No Abstract] [Full Text] [Related]
4. Antimicrobial Susceptibility of
Gales AC; Seifert H; Gur D; Castanheira M; Jones RN; Sader HS
Open Forum Infect Dis; 2019 Mar; 6(Suppl 1):S34-S46. PubMed ID: 30895213
[TBL] [Abstract][Full Text] [Related]
5. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
[TBL] [Abstract][Full Text] [Related]
6. Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia.
Biagi M; Vialichka A; Jurkovic M; Wu T; Shajee A; Lee M; Patel S; Mendes RE; Wenzler E
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571820
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments.
Wei C; Ni W; Cai X; Zhao J; Cui J
PLoS One; 2016; 11(3):e0152132. PubMed ID: 26999818
[TBL] [Abstract][Full Text] [Related]
8.
Karlowsky JA; Hackel MA; McLeod SM; Miller AA
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0078122. PubMed ID: 36005804
[TBL] [Abstract][Full Text] [Related]
9. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
[TBL] [Abstract][Full Text] [Related]
10. Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options.
Castanheira M; Mendes RE; Jones RN
Clin Infect Dis; 2014 Dec; 59 Suppl 6():S367-73. PubMed ID: 25371512
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
[TBL] [Abstract][Full Text] [Related]
12. Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole.
Biagi M; Tan X; Wu T; Jurkovic M; Vialichka A; Meyer K; Mendes RE; Wenzler E
J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31748318
[No Abstract] [Full Text] [Related]
13. Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals.
Falagas ME; Skalidis T; Vardakas KZ; Voulgaris GL; Papanikolaou G; Legakis N;
Int J Antimicrob Agents; 2018 Aug; 52(2):269-271. PubMed ID: 29559273
[TBL] [Abstract][Full Text] [Related]
14. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients.
Liang W; Liu XF; Huang J; Zhu DM; Li J; Zhang J
BMC Infect Dis; 2011 Apr; 11():109. PubMed ID: 21521536
[TBL] [Abstract][Full Text] [Related]
15. Detection of multidrug resistant environmental isolates of
Govender R; Amoah ID; Kumari S; Bux F; Stenström TA
J Environ Sci Health A Tox Hazard Subst Environ Eng; 2021; 56(2):213-225. PubMed ID: 33378222
[No Abstract] [Full Text] [Related]
16. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999).
Gales AC; Jones RN; Forward KR; Liñares J; Sader HS; Verhoef J
Clin Infect Dis; 2001 May; 32 Suppl 2():S104-13. PubMed ID: 11320451
[TBL] [Abstract][Full Text] [Related]
17. In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.
Ratjen A; Yau Y; Wettlaufer J; Matukas L; Zlosnik JE; Speert DP; LiPuma JJ; Tullis E; Waters V
Antimicrob Agents Chemother; 2015 Jan; 59(1):711-3. PubMed ID: 25348526
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant Acinetobacter baumannii.
Seifert H; Stefanik D; Olesky M; Higgins PG
Int J Antimicrob Agents; 2020 Jan; 55(1):105829. PubMed ID: 31669740
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial.
Halstead DC; Abid J; Dowzicky MJ
J Infect; 2007 Jul; 55(1):49-57. PubMed ID: 17250897
[TBL] [Abstract][Full Text] [Related]
20. Levofloxacin Efflux and smeD in Clinical Isolates of Stenotrophomonas maltophilia.
Chong SY; Lee K; Chung HS; Hong SG; Suh Y; Chong Y
Microb Drug Resist; 2017 Mar; 23(2):163-168. PubMed ID: 27294684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
